Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Kidney Transplantation | 69 | 2020 | 348 | 13.780 |
Why?
|
Pancreas Transplantation | 42 | 2018 | 80 | 9.680 |
Why?
|
Tissue Donors | 30 | 2018 | 167 | 6.440 |
Why?
|
Graft Rejection | 35 | 2019 | 149 | 5.610 |
Why?
|
Graft Survival | 32 | 2020 | 228 | 3.710 |
Why?
|
Immunosuppressive Agents | 22 | 2019 | 167 | 3.640 |
Why?
|
Tissue and Organ Procurement | 13 | 2018 | 69 | 3.220 |
Why?
|
Delayed Graft Function | 9 | 2020 | 33 | 2.820 |
Why?
|
Immunosuppression | 16 | 2019 | 80 | 2.740 |
Why?
|
Kidney Failure, Chronic | 15 | 2018 | 518 | 2.590 |
Why?
|
Antilymphocyte Serum | 8 | 2015 | 17 | 1.830 |
Why?
|
Donor Selection | 4 | 2019 | 31 | 1.700 |
Why?
|
Humans | 114 | 2020 | 29093 | 1.580 |
Why?
|
Retrospective Studies | 31 | 2019 | 3111 | 1.540 |
Why?
|
Kidney | 14 | 2020 | 485 | 1.470 |
Why?
|
Organ Preservation | 6 | 2014 | 13 | 1.410 |
Why?
|
Regenerative Medicine | 12 | 2015 | 187 | 1.370 |
Why?
|
Tissue and Organ Harvesting | 6 | 2014 | 35 | 1.350 |
Why?
|
Adult | 46 | 2020 | 8420 | 1.350 |
Why?
|
Antibodies, Monoclonal | 8 | 2009 | 196 | 1.340 |
Why?
|
Middle Aged | 50 | 2020 | 10829 | 1.310 |
Why?
|
Regeneration | 10 | 2016 | 167 | 1.270 |
Why?
|
Organ Transplantation | 8 | 2013 | 65 | 1.240 |
Why?
|
Cadaver | 12 | 2018 | 143 | 1.190 |
Why?
|
Male | 54 | 2020 | 17807 | 1.170 |
Why?
|
Female | 55 | 2020 | 18164 | 1.130 |
Why?
|
Nephrectomy | 5 | 2019 | 114 | 1.110 |
Why?
|
Tissue Engineering | 10 | 2016 | 608 | 1.050 |
Why?
|
Postoperative Complications | 7 | 2018 | 670 | 1.040 |
Why?
|
Follow-Up Studies | 16 | 2019 | 2108 | 0.970 |
Why?
|
Survival Rate | 11 | 2018 | 795 | 0.920 |
Why?
|
Patient Selection | 8 | 2018 | 257 | 0.920 |
Why?
|
Transplantation, Homologous | 10 | 2014 | 113 | 0.900 |
Why?
|
Diabetes Mellitus | 3 | 2015 | 366 | 0.890 |
Why?
|
Liver Transplantation | 13 | 2012 | 111 | 0.860 |
Why?
|
Tissue Scaffolds | 12 | 2016 | 386 | 0.850 |
Why?
|
Time Factors | 19 | 2017 | 2001 | 0.850 |
Why?
|
Cytomegalovirus Infections | 5 | 2014 | 25 | 0.810 |
Why?
|
Extracellular Matrix | 9 | 2016 | 226 | 0.800 |
Why?
|
C-Peptide | 3 | 2018 | 25 | 0.790 |
Why?
|
Isoantibodies | 3 | 2014 | 10 | 0.780 |
Why?
|
Mycophenolic Acid | 6 | 2008 | 28 | 0.780 |
Why?
|
Bioengineering | 9 | 2015 | 67 | 0.770 |
Why?
|
Cold Ischemia | 2 | 2018 | 7 | 0.740 |
Why?
|
Treatment Outcome | 21 | 2017 | 3099 | 0.730 |
Why?
|
Extracorporeal Circulation | 2 | 2011 | 11 | 0.720 |
Why?
|
Tacrolimus | 10 | 2008 | 44 | 0.720 |
Why?
|
Living Donors | 5 | 2015 | 51 | 0.720 |
Why?
|
Immunoglobulin G | 4 | 2004 | 104 | 0.710 |
Why?
|
Diabetes Mellitus, Type 1 | 10 | 2014 | 180 | 0.710 |
Why?
|
Portal Vein | 2 | 2013 | 16 | 0.710 |
Why?
|
Antibodies, Neoplasm | 3 | 2009 | 12 | 0.700 |
Why?
|
Aged | 20 | 2019 | 9487 | 0.690 |
Why?
|
Steroids | 3 | 2015 | 36 | 0.680 |
Why?
|
Prognosis | 9 | 2018 | 1362 | 0.660 |
Why?
|
Endarterectomy | 1 | 2018 | 7 | 0.660 |
Why?
|
Renal Artery | 1 | 2018 | 43 | 0.650 |
Why?
|
Antiviral Agents | 5 | 2010 | 100 | 0.650 |
Why?
|
Health Services Accessibility | 3 | 2017 | 231 | 0.650 |
Why?
|
Risk Factors | 14 | 2018 | 3531 | 0.640 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 109 | 0.560 |
Why?
|
Young Adult | 9 | 2019 | 2402 | 0.540 |
Why?
|
Renal Insufficiency | 2 | 2017 | 53 | 0.530 |
Why?
|
Kidney Neoplasms | 2 | 2019 | 192 | 0.530 |
Why?
|
Drainage | 2 | 2013 | 49 | 0.520 |
Why?
|
Uremia | 1 | 2015 | 9 | 0.520 |
Why?
|
Kidney Diseases | 3 | 2014 | 239 | 0.520 |
Why?
|
Embolization, Therapeutic | 2 | 2019 | 79 | 0.520 |
Why?
|
Ganciclovir | 4 | 2008 | 14 | 0.520 |
Why?
|
Transplantation Conditioning | 1 | 2014 | 11 | 0.510 |
Why?
|
Pancreas | 6 | 2016 | 79 | 0.510 |
Why?
|
Radiography, Interventional | 1 | 2014 | 35 | 0.500 |
Why?
|
Ossification, Heterotopic | 1 | 2014 | 14 | 0.500 |
Why?
|
Glomerular Filtration Rate | 6 | 2018 | 287 | 0.490 |
Why?
|
Gastrointestinal Tract | 3 | 2012 | 29 | 0.480 |
Why?
|
North Carolina | 6 | 2018 | 1423 | 0.460 |
Why?
|
Animals | 18 | 2015 | 7297 | 0.460 |
Why?
|
Perfusion | 4 | 2015 | 64 | 0.440 |
Why?
|
Catheter Ablation | 1 | 2013 | 62 | 0.440 |
Why?
|
Incidence | 6 | 2018 | 1119 | 0.440 |
Why?
|
Azathioprine | 3 | 2011 | 8 | 0.430 |
Why?
|
Polyomavirus Infections | 4 | 2006 | 21 | 0.420 |
Why?
|
Death, Sudden, Cardiac | 2 | 2020 | 59 | 0.420 |
Why?
|
Adolescent | 9 | 2019 | 3254 | 0.420 |
Why?
|
Death | 2 | 2009 | 41 | 0.420 |
Why?
|
Age Factors | 7 | 2019 | 1108 | 0.420 |
Why?
|
Transplantation Tolerance | 1 | 2011 | 14 | 0.420 |
Why?
|
Kidney Function Tests | 3 | 2018 | 102 | 0.410 |
Why?
|
Reoperation | 6 | 2019 | 203 | 0.410 |
Why?
|
Gout | 1 | 2011 | 14 | 0.410 |
Why?
|
Thiazoles | 1 | 2011 | 32 | 0.410 |
Why?
|
Thrombosis | 1 | 2012 | 60 | 0.410 |
Why?
|
Fibrinolytic Agents | 1 | 2012 | 70 | 0.400 |
Why?
|
Thrombectomy | 1 | 2012 | 58 | 0.400 |
Why?
|
Heart Arrest | 1 | 2011 | 39 | 0.390 |
Why?
|
Anticoagulants | 1 | 2012 | 120 | 0.390 |
Why?
|
Sirolimus | 3 | 2008 | 35 | 0.370 |
Why?
|
Prospective Studies | 6 | 2018 | 2019 | 0.350 |
Why?
|
Creatinine | 5 | 2016 | 174 | 0.350 |
Why?
|
Islets of Langerhans Transplantation | 4 | 2014 | 40 | 0.340 |
Why?
|
Blood Group Incompatibility | 3 | 2016 | 11 | 0.340 |
Why?
|
ABO Blood-Group System | 3 | 2016 | 19 | 0.330 |
Why?
|
Insulin | 4 | 2018 | 346 | 0.290 |
Why?
|
Child, Preschool | 4 | 2019 | 1167 | 0.290 |
Why?
|
Tumor Virus Infections | 2 | 2004 | 20 | 0.290 |
Why?
|
Survival Analysis | 7 | 2019 | 440 | 0.280 |
Why?
|
Stem Cell Transplantation | 5 | 2015 | 203 | 0.280 |
Why?
|
Anemia, Hemolytic | 1 | 2005 | 6 | 0.270 |
Why?
|
United States | 7 | 2017 | 3630 | 0.270 |
Why?
|
Erythrocytes | 1 | 2005 | 43 | 0.270 |
Why?
|
Rabbits | 3 | 2014 | 185 | 0.260 |
Why?
|
Hypertension | 1 | 2011 | 906 | 0.250 |
Why?
|
Diabetic Nephropathies | 1 | 2005 | 195 | 0.240 |
Why?
|
Infant | 4 | 2019 | 969 | 0.230 |
Why?
|
Nephritis, Interstitial | 1 | 2003 | 9 | 0.230 |
Why?
|
Hepatitis C | 2 | 2019 | 38 | 0.220 |
Why?
|
Prednisone | 1 | 2002 | 43 | 0.210 |
Why?
|
Registries | 2 | 2016 | 278 | 0.210 |
Why?
|
Academic Medical Centers | 1 | 2003 | 150 | 0.210 |
Why?
|
Postoperative Period | 2 | 2014 | 91 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 1 | 2002 | 90 | 0.200 |
Why?
|
Child | 3 | 2019 | 2219 | 0.190 |
Why?
|
Chi-Square Distribution | 3 | 2017 | 293 | 0.190 |
Why?
|
Length of Stay | 2 | 2014 | 292 | 0.190 |
Why?
|
Cyclosporine | 5 | 1993 | 34 | 0.180 |
Why?
|
RNA | 1 | 2020 | 88 | 0.170 |
Why?
|
Aged, 80 and over | 2 | 2017 | 3717 | 0.170 |
Why?
|
Antibodies | 1 | 1998 | 53 | 0.170 |
Why?
|
Acyclovir | 1 | 1998 | 8 | 0.170 |
Why?
|
Hypoglycemia | 1 | 1998 | 41 | 0.170 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 320 | 0.160 |
Why?
|
Treatment Failure | 2 | 2017 | 159 | 0.160 |
Why?
|
Biopsy | 4 | 2014 | 241 | 0.160 |
Why?
|
Cohort Studies | 3 | 2011 | 1687 | 0.160 |
Why?
|
Odds Ratio | 2 | 2016 | 447 | 0.150 |
Why?
|
Apolipoproteins | 2 | 2016 | 196 | 0.150 |
Why?
|
Blood Transfusion | 2 | 2014 | 64 | 0.140 |
Why?
|
Islets of Langerhans | 2 | 2016 | 74 | 0.140 |
Why?
|
Lipoproteins, HDL | 2 | 2016 | 247 | 0.140 |
Why?
|
Bioreactors | 2 | 2013 | 59 | 0.140 |
Why?
|
Microvessels | 1 | 2015 | 23 | 0.130 |
Why?
|
Healthcare Disparities | 1 | 2017 | 153 | 0.130 |
Why?
|
Kidney Glomerulus | 1 | 2015 | 30 | 0.130 |
Why?
|
Caveolin 1 | 1 | 2015 | 13 | 0.130 |
Why?
|
Brain Death | 2 | 2014 | 27 | 0.130 |
Why?
|
Preoperative Period | 1 | 2014 | 31 | 0.130 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2015 | 100 | 0.130 |
Why?
|
Hemodynamics | 1 | 2015 | 148 | 0.130 |
Why?
|
Metaplasia | 1 | 2014 | 20 | 0.130 |
Why?
|
HLA Antigens | 2 | 2014 | 35 | 0.130 |
Why?
|
Blood Loss, Surgical | 1 | 2014 | 45 | 0.130 |
Why?
|
Immune Tolerance | 2 | 2014 | 67 | 0.120 |
Why?
|
Insulin-Secreting Cells | 1 | 2014 | 53 | 0.120 |
Why?
|
Bioprosthesis | 1 | 2014 | 55 | 0.120 |
Why?
|
Acute Disease | 4 | 2012 | 239 | 0.120 |
Why?
|
Preoperative Care | 1 | 2014 | 110 | 0.120 |
Why?
|
Regional Blood Flow | 1 | 2013 | 82 | 0.120 |
Why?
|
Organ Culture Techniques | 1 | 2013 | 38 | 0.120 |
Why?
|
Insurance Coverage | 1 | 2013 | 74 | 0.110 |
Why?
|
Disease Progression | 1 | 2014 | 572 | 0.110 |
Why?
|
Abdomen | 1 | 2012 | 42 | 0.110 |
Why?
|
Intestines | 2 | 2010 | 54 | 0.110 |
Why?
|
Kidney Tubular Necrosis, Acute | 1 | 1992 | 2 | 0.110 |
Why?
|
Liver | 2 | 2012 | 464 | 0.110 |
Why?
|
Drug Administration Schedule | 2 | 2003 | 246 | 0.110 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2011 | 1379 | 0.110 |
Why?
|
Waiting Lists | 2 | 2013 | 30 | 0.110 |
Why?
|
Cells, Cultured | 1 | 2014 | 799 | 0.110 |
Why?
|
Blood Grouping and Crossmatching | 2 | 2016 | 9 | 0.110 |
Why?
|
Warfarin | 1 | 2012 | 30 | 0.100 |
Why?
|
Postoperative Hemorrhage | 1 | 2012 | 38 | 0.100 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 38 | 0.100 |
Why?
|
Gout Suppressants | 1 | 2011 | 4 | 0.100 |
Why?
|
Aspirin | 1 | 2012 | 61 | 0.100 |
Why?
|
Drug Therapy, Combination | 2 | 2003 | 273 | 0.100 |
Why?
|
Hepatitis, Viral, Human | 1 | 1991 | 4 | 0.100 |
Why?
|
Heparin | 1 | 2012 | 75 | 0.100 |
Why?
|
Drug Interactions | 1 | 2011 | 80 | 0.100 |
Why?
|
African Americans | 2 | 2016 | 1373 | 0.100 |
Why?
|
Warm Ischemia | 1 | 2011 | 8 | 0.100 |
Why?
|
General Surgery | 1 | 2012 | 81 | 0.100 |
Why?
|
Transplantation Immunology | 4 | 2015 | 27 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 1079 | 0.100 |
Why?
|
Ethnic Groups | 1 | 2013 | 440 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 159 | 0.090 |
Why?
|
Immunotherapy | 1 | 2010 | 69 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2017 | 709 | 0.090 |
Why?
|
Serum Albumin | 1 | 2010 | 53 | 0.090 |
Why?
|
Solutions | 1 | 2009 | 26 | 0.090 |
Why?
|
Hyperglycemia | 1 | 2010 | 82 | 0.090 |
Why?
|
Stem Cells | 4 | 2014 | 292 | 0.090 |
Why?
|
Risk Assessment | 2 | 2017 | 1305 | 0.090 |
Why?
|
Glomerulonephritis, IGA | 1 | 2009 | 6 | 0.090 |
Why?
|
Asphyxia | 1 | 2009 | 6 | 0.090 |
Why?
|
Infarction | 1 | 2009 | 5 | 0.090 |
Why?
|
Suicide | 1 | 2009 | 17 | 0.090 |
Why?
|
T-Lymphocytes | 1 | 2009 | 114 | 0.090 |
Why?
|
Leukopenia | 1 | 2008 | 7 | 0.090 |
Why?
|
Cause of Death | 2 | 2007 | 220 | 0.080 |
Why?
|
Ischemia | 1 | 2009 | 92 | 0.080 |
Why?
|
Compartment Syndromes | 1 | 2009 | 38 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2011 | 464 | 0.080 |
Why?
|
Diabetes Complications | 1 | 2010 | 171 | 0.080 |
Why?
|
Inflammation | 1 | 2012 | 507 | 0.080 |
Why?
|
Intraoperative Period | 1 | 2007 | 37 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2007 | 859 | 0.080 |
Why?
|
Age Distribution | 1 | 2007 | 198 | 0.080 |
Why?
|
Cryopreservation | 1 | 2007 | 42 | 0.070 |
Why?
|
Body Size | 1 | 2006 | 31 | 0.070 |
Why?
|
Multivariate Analysis | 3 | 2017 | 637 | 0.070 |
Why?
|
Nephrons | 1 | 2006 | 10 | 0.070 |
Why?
|
Polyomavirus | 1 | 2006 | 1 | 0.070 |
Why?
|
Rho(D) Immune Globulin | 1 | 2005 | 2 | 0.070 |
Why?
|
Glycosuria, Renal | 1 | 2005 | 3 | 0.070 |
Why?
|
Hemolysis | 1 | 2005 | 12 | 0.070 |
Why?
|
Anastomosis, Surgical | 2 | 2003 | 49 | 0.070 |
Why?
|
Organogenesis | 2 | 2016 | 15 | 0.070 |
Why?
|
Lymphocytes | 1 | 2005 | 53 | 0.070 |
Why?
|
Quality of Health Care | 1 | 2006 | 134 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2004 | 24 | 0.060 |
Why?
|
BK Virus | 1 | 2004 | 7 | 0.060 |
Why?
|
Phenotype | 2 | 2016 | 629 | 0.060 |
Why?
|
Portal System | 1 | 2003 | 6 | 0.060 |
Why?
|
Attitude to Health | 1 | 2004 | 148 | 0.060 |
Why?
|
Triglycerides | 1 | 2004 | 214 | 0.060 |
Why?
|
Digestive System Surgical Procedures | 1 | 2003 | 20 | 0.060 |
Why?
|
Transplants | 2 | 2014 | 22 | 0.060 |
Why?
|
Liver Regeneration | 2 | 2012 | 23 | 0.050 |
Why?
|
Cholesterol | 1 | 2004 | 229 | 0.050 |
Why?
|
Muromonab-CD3 | 4 | 2002 | 5 | 0.050 |
Why?
|
Quality of Life | 3 | 2015 | 816 | 0.050 |
Why?
|
Bile Ducts | 1 | 2001 | 18 | 0.050 |
Why?
|
Histocompatibility Testing | 2 | 2014 | 15 | 0.050 |
Why?
|
Biocompatible Materials | 2 | 2012 | 210 | 0.050 |
Why?
|
Cold Temperature | 1 | 2001 | 39 | 0.050 |
Why?
|
Databases, Factual | 2 | 2017 | 332 | 0.050 |
Why?
|
Long-Term Care | 1 | 2000 | 21 | 0.050 |
Why?
|
Remission, Spontaneous | 1 | 2019 | 14 | 0.040 |
Why?
|
RNA, Viral | 1 | 2019 | 49 | 0.040 |
Why?
|
Angiography | 1 | 2019 | 75 | 0.040 |
Why?
|
Hepacivirus | 1 | 2019 | 37 | 0.040 |
Why?
|
Viral Load | 1 | 2019 | 64 | 0.040 |
Why?
|
Tennessee | 1 | 1998 | 97 | 0.040 |
Why?
|
Costs and Cost Analysis | 1 | 1998 | 88 | 0.040 |
Why?
|
Administration, Oral | 1 | 1998 | 169 | 0.040 |
Why?
|
Neoplasm Staging | 1 | 2019 | 436 | 0.040 |
Why?
|
Blood Glucose | 1 | 1998 | 466 | 0.030 |
Why?
|
Protein Array Analysis | 1 | 2015 | 16 | 0.030 |
Why?
|
Corrosion Casting | 1 | 2015 | 9 | 0.030 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 20 | 0.030 |
Why?
|
Social Support | 1 | 2017 | 163 | 0.030 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2015 | 92 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 103 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 148 | 0.030 |
Why?
|
Haplotypes | 1 | 2015 | 220 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 871 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 1998 | 1356 | 0.030 |
Why?
|
Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
Forecasting | 1 | 2014 | 133 | 0.030 |
Why?
|
Antigens | 1 | 2013 | 31 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 1218 | 0.030 |
Why?
|
Detergents | 1 | 2013 | 17 | 0.030 |
Why?
|
Chickens | 1 | 2013 | 40 | 0.030 |
Why?
|
Pressure | 1 | 2013 | 54 | 0.030 |
Why?
|
Sus scrofa | 1 | 2013 | 44 | 0.030 |
Why?
|
Quality Assurance, Health Care | 2 | 2004 | 61 | 0.030 |
Why?
|
Capsules | 1 | 2012 | 14 | 0.030 |
Why?
|
Neovascularization, Physiologic | 1 | 2013 | 106 | 0.030 |
Why?
|
Renal Circulation | 1 | 1992 | 13 | 0.030 |
Why?
|
Skin, Artificial | 1 | 2012 | 31 | 0.030 |
Why?
|
Larynx | 1 | 2012 | 19 | 0.030 |
Why?
|
Chondroitin Sulfates | 1 | 2012 | 22 | 0.030 |
Why?
|
Hepatocytes | 1 | 2012 | 74 | 0.030 |
Why?
|
Vascular Resistance | 1 | 1992 | 28 | 0.030 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 30 | 0.030 |
Why?
|
Pancreatic Diseases | 1 | 2012 | 16 | 0.030 |
Why?
|
Liver Failure | 1 | 2012 | 17 | 0.030 |
Why?
|
Intestinal Diseases | 1 | 2012 | 18 | 0.030 |
Why?
|
Dogs | 1 | 1992 | 117 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2014 | 436 | 0.030 |
Why?
|
Swine | 1 | 2012 | 201 | 0.030 |
Why?
|
Cell Transplantation | 1 | 2012 | 63 | 0.030 |
Why?
|
Blood Vessel Prosthesis | 1 | 2012 | 78 | 0.030 |
Why?
|
Developmental Biology | 1 | 2011 | 7 | 0.030 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 5 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2013 | 519 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 1991 | 21 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 1991 | 22 | 0.030 |
Why?
|
Cattle | 1 | 2011 | 100 | 0.030 |
Why?
|
History, 20th Century | 1 | 2011 | 68 | 0.020 |
Why?
|
Corneal Transplantation | 1 | 2010 | 13 | 0.020 |
Why?
|
Collagen | 1 | 2012 | 217 | 0.020 |
Why?
|
Chondrocytes | 1 | 2011 | 71 | 0.020 |
Why?
|
Wound Healing | 1 | 2012 | 182 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 573 | 0.020 |
Why?
|
European Continental Ancestry Group | 1 | 2015 | 1131 | 0.020 |
Why?
|
Trachea | 1 | 2010 | 55 | 0.020 |
Why?
|
Ultrasonography | 1 | 1992 | 345 | 0.020 |
Why?
|
Heart | 1 | 2010 | 161 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2012 | 250 | 0.020 |
Why?
|
Transplantation | 1 | 1989 | 12 | 0.020 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2008 | 21 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2010 | 176 | 0.020 |
Why?
|
Models, Biological | 1 | 2010 | 373 | 0.020 |
Why?
|
Chronic Disease | 3 | 1993 | 369 | 0.020 |
Why?
|
Sex Factors | 2 | 2004 | 631 | 0.020 |
Why?
|
Heart Failure | 1 | 2012 | 568 | 0.020 |
Why?
|
Necrosis | 1 | 2006 | 53 | 0.020 |
Why?
|
Drug Therapy | 1 | 2006 | 16 | 0.020 |
Why?
|
Mice | 1 | 2011 | 2368 | 0.020 |
Why?
|
Disease Management | 1 | 2006 | 114 | 0.020 |
Why?
|
Factor Analysis, Statistical | 1 | 2004 | 70 | 0.020 |
Why?
|
Heart Transplantation | 1 | 2004 | 26 | 0.020 |
Why?
|
Needs Assessment | 1 | 2004 | 66 | 0.020 |
Why?
|
Health Surveys | 1 | 2004 | 191 | 0.020 |
Why?
|
Psychometrics | 1 | 2004 | 129 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 546 | 0.010 |
Why?
|
Liver Function Tests | 2 | 1993 | 19 | 0.010 |
Why?
|
Morbidity | 1 | 2002 | 91 | 0.010 |
Why?
|
Mortality | 1 | 2003 | 109 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2002 | 281 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 2 | 1993 | 148 | 0.010 |
Why?
|
Risk | 1 | 2002 | 289 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2004 | 863 | 0.010 |
Why?
|
Hepatectomy | 1 | 2001 | 66 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1993 | 4 | 0.010 |
Why?
|
Bilirubin | 1 | 1993 | 22 | 0.010 |
Why?
|
Communicable Diseases | 1 | 1993 | 19 | 0.010 |
Why?
|
Drug Resistance | 1 | 1993 | 36 | 0.010 |
Why?
|
Sex Characteristics | 1 | 1993 | 167 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1993 | 454 | 0.010 |
Why?
|
Renal Dialysis | 1 | 1993 | 259 | 0.010 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 1989 | 3 | 0.010 |
Why?
|
Wisconsin | 1 | 1989 | 18 | 0.010 |
Why?
|
California | 1 | 1989 | 60 | 0.010 |
Why?
|
Pregnancy | 1 | 1989 | 815 | 0.000 |
Why?
|